A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
Status:
Completed
Trial end date:
2000-04-01
Target enrollment:
Participant gender:
Summary
This is a placebo controlled study evaluating the role of fludarabine (a nucleoside analog
targeting both resting and proliferating lymphocytes) in the treatment of moderate to severe
psoriotic arthritis. Patients should have failed at least one disease modifying antirheumatic
drug.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)